hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-12. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
=== Eligibility === In the 11th version of the International Classification of Diseases (ICD-11), the diagnosis is known as gender incongruence. ICD-11 states that "Gender variant behaviour and preferences alone are not a basis for assigning the diagnosis." The US Diagnostic and Statistical Manual of Mental Disorders (DSM) names it gender dysphoria (in version 5). Some people who are validly diagnosed have no desire for all or some parts of hormone replacement therapy, or gender affirming surgery, and/or are not appropriate candidates for such treatment. The general standards for diagnosing, as well as treating distress caused by gender incongruence or gender dysphoria are outlined in the WPATH Standards of Care for the Health of Transgender and Gender Diverse People. As of February 2023, the most recent version of the standards is Version 8, called SOC8 in short. According to the standards of care, "Gender Dysphoria describes a state of distress or discomfort that may be experienced because a person's gender identity differs from that which is physically and/or socially attributed to their sex assigned at birth... Not all transgender and gender diverse people experience gender dysphoria." Gender nonconformity is not the same as gender dysphoria; nonconformity, according to the standards of care, is not a pathology and does not require medical treatment. The WPATH Standards of Care in the latest version 8 from February 2023, follow an informed consent model, which is the default approach that most medical professionals administering gender-affirming care follow today.
== Treatment == Once wound dehiscence occurs, it can be treated by allowing granulation, re-cutting and suturing the edges, and providing prophylactic antibiotics. Exposure to the air, debridement, and, if indicated, frequent dressing changes also help.
=== RFLP === A restriction fragment length polymorphism results in the cleavage (or absence thereof) of DNA for a specific mutation by a selected restriction enzyme that will not cleave the wildtype DNA. In a study using a mixture of wildtype and mutation containing DNA amplified by regular PCR or COLD-PCR, COLD-PCR preceding RFLP analysis was shown to improve the mutation detection by 10-20 fold.
Pine nuts, also called piñón (Spanish: [piˈɲon]), pinoli (Italian: [piˈnɔːli]), or pignoli, are the edible seeds of pines (family Pinaceae, genus Pinus). According to the Food and Agriculture Organization, only 29 species provide edible nuts, while 20 are traded locally or internationally owing to their seed size being large enough to be worth harvesting; in other pines, the seeds are also edible but are too small to be of notable value as human food. The biggest exporters of pine nuts are China, Russia, North Korea, and Pakistan. As pines are gymnosperms, not angiosperms (flowering plants), pine nuts are not "true nuts"; they are not botanical fruits, the seed not being enclosed in an ovary which develops into the fruit, but simply bare seeds—"gymnosperm" meaning literally "naked seed" (from Ancient Greek: γυμνός, romanized: gymnos, lit. 'naked' and σπέρμα, sperma, 'seed'). The similarity of pine nuts to some angiosperm fruits is an example of convergent evolution.
==== Interpretation of results ==== HOMA-IR < 2: normal insulin sensitivity HOMA-IR > 2: possible insulin resistance HOMA-IR > 2,5: probable insulin resistance HOMA-IR > 5: typical results for type 2 diabetes SPINA-GR 1,41–9,00 mol/s: normal insulin sensitivity SPINA-GR ≤ 1,40 mol/s: insulin resistance SPINA-GR < 1,35 mol/s: typical results for type 2 diabetes
Sources: en.wikipedia.org
== Growth and physiology == The invasive apparatus of this species consists of non-adhesive, crescent-shaped conidia that are ingested by hosts and lodge in the esophagus or gut. The sickle shape of the conidia is also contributes to the ability of the fungus to pierce through the host cuticle. In the laboratory, cultures of the fungus can be cultivated on agar containing yeast hydrolysate or glucose, though growth is much slower on glucose. The fungus grows rapidly on water-agar and produces chlamydospores, implying an oligotrophic physiology.
With this new logo, Outback then went on an aggressive remodeling campaign, starting in 2008, renovating most of their locations, along with opening brand new ones, for a fresher, more modern look to their business model. This included the removal of their iconic neon signs for more energy efficient LEDs, and the switch from a dark, rustic feel to a brighter, more vibrant look. Today, few original-style Outback locations remain, with most of them either abandoned for newer locations, or renovated. On June 14, 2007, OSI Restaurant Partners completed a stock repurchase plan, and the company became privately held. In April 2012, Bloomin' Brands, the current owner of Outback Steakhouse, filed with the SEC to raise up to $300 million in an initial public offering. Bloomin' Brands, Inc. became a publicly traded company on NASDAQ under the ticker symbol "BLMN." Most Outback locations are corporately owned by Bloomin Brands. However, locations in California, Nevada, Arizona, Colorado, and New Mexico are separately owned by a corporate franchisee, Out West Restaurant Group. Outback Steakhouse currently operates over 1,000 locations worldwide, with 670 in the United States. In October 2025, Outback Steakhouse closed several locations across multiple U.S. states as part of a broader turnaround plan by its parent company, Bloomin' Brands.
Glycolipid transfer protein is a cytosolic protein that catalyses the transfer of glycolipids between different intracellular membranes. It was discovered by Raymond J. Metz and Norman S. Radin in 1980 and partially purified and characterized in 1982. Recent reviews on structure and possible function are available. This protein transports primarily different glycosphingolipids and glyceroglycolipids between intracellular membranes, but not phospholipids. It might be also involved in translocation of glucosylceramides. It was found in brain, kidney, spleen, lung, cerebellum, liver and heart.
ethyl The alkyl functional group derived from ethane, consisting of two carbon atoms covalently bonded to each other and fully saturated with bonds to hydrogen atoms, with the chemical formula –CH2CH3. It is a common substituent in numerous organic compounds, though it may also exist independently as an ion or radical. In IUPAC nomenclature, the presence of an ethyl substituent may be indicated with the prefix ethyl in the name of the compound, or with the abbreviation Et in chemical formulae; e.g. ethyl alcohol (ethanol), which is often written with the formula CH3CH2OH or EtOH.
Histidine deprotonates serine Serine substitutes in at the amide bond The protonated histidine makes the amine a better leaving group and the oxyanion collapses to form the ester. Water enters the triad and cleaves the ester bond, releasing serine.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.